View Dr. Moore, Jr.'s Curriculum Vitae in Word Format

CV for Dennis F. Moore, Jr., M.D. Page 1

DENNIS F. MOORE, JR.CURRICULUM VITAE

Personal Data:

Office Address and Phone

818 N. Emporia, Suite 403

Wichita, Kansas 67214

(316) 262-4467; fax (316) 262-0706

Date of birth June 6Place of birth New Orleans, LouisianaCurrent Citizenship U.S.A.

Professional Registration/Licensure:

Year State

1990 KansasEducation

Year Degree Institution

8/1979-5/1982 -- Washington University, St. Louis, Missouri

8/1982-5/1983 B.A. University of Kansas, Lawrence, Kansas

8/1983-5/1987 M.D. University of Kansas School of MedicineKansas City, Kansas

Postgraduate Education:

Year Degree Institution

1987-90 Resident, Internal Medicine

Baylor College of MedicineHouston, Texas

1990-93 Fellow, Medical Oncology and Hematology

University of Texas, M.D. Anderson Cancer Center Houston, Texas

7-12/1991 Fellow, Hematology Baylor College of Medicine, Houston, Texas

2/07p&tforma.frm


Academic Appointments: (In reverse chronological order)

Month & Year Position Institution

7/1/04- Clinical Professor of Medicine

University of Kansas School of Medicine-WichitaWichita, Kansas

7/1/99- Clinical Associate Professor University of Kansas School of Medicine-WichitaWichita, Kansas

7/1996-6/1998

Clinical Assistant Professor University of Kansas School of Medicine-WichitaWichita, Kansas

7/1994-6/1996

Assistant Professor University of Kansas School of Medicine-WichitaWichita, Kansas

7/1994- Adjunct Assistant Professor of Medicine


7/1993-6/1994

Assistant Professor & Assistant Internist


11/1991-6/1993

Junior Faculty Associate University of Texas, M.D. Anderson Cancer Center Houston, Texas

Certification:

Board Date Recertification

American Board of Internal Medicine 9/1991 11/2001

Subspecialty (ABIM) Medical Oncology 11/1993 11/2001

Subspecialty (ABIM) Hematology 11/1996

Professional Societies and Affiliations: (Including offices held)

Year

1994

Organization

National Cancer Institution (NCI)M.D. AndersonUniversity of RochesterNational Surgical Adjuvant Breast & Bowel Project (NSABP)Wichita Community Clinical Oncology Program (WCCOP)Leukemia Society of America (Kansas Chapter)Southwest Oncology Group (SWOG)

Office

Board Member

2/07p&tforma.frm


Professional Societies and Affiliations: (Including offices held) - continued

1/99-American College of Physicians FellowAmerican Society of Internal MedicineTexas Society of Internal MedicineAmerican Society of HematologyAmerican Society of Clinical OncologyAmerican Society for Blood and Marrow TransplantationKansas Society of Clinical Oncology

1997- International Society for Hematotherapy and Graft Engineering Secretary

2004 Journal of Rheumatology ReviewerKansas Chapter of American Society of Clinical Oncology

2006 - President

Honors and Awards: (Include service on national and international professional committees, study sections, offices in professional societies, membership of editorial boards, positions as reviewer for scientific journals or examiner for board examinations, etc.)

Year Organization

Washington University, St. Louis, Missouri1981-82 President, Xi Chapter of Tau Kappa Epsilon

1983-87 University of Kansas School of MedicineSummer Research FellowshipNell Educational Trust Scholarship

1987 Cieneguilla, PeruSt. Francis Award, Parroquia de Cieneguilla

American Cancer Society1990-91 Junior Investigator Award1992-93 Research Fellowship

University of Texas, M.D. Anderson Cancer Center1990-91 Clifton D. Howe Award for Excellence in Clinical Oncology1991-92 Competitive Research Award1991-92 Sandoz Research Fellow Award (Dept. Hematology)1992-93 Competitive Research Award6/9/1993 Outstanding Chief Fellow (Special Award)

Schwachmann Syndrome Foundation and Registry4/1995- Advisory Board

Leukemia Society of America8/1997 Dr. Dennis Moore, Sr. Award2/2001- Preferred Health Systems Specialty Advisory Board5/2004 Clinical Professor – KU School of Medicine4/20049/2005

Loyal Order of the MooseVia Christi Regional Medical Center St. Luke Physician Recognition Award for the core value of Human Dignity

2/07p&tforma.frm


Research Activities:

1. Brief statement of area of research interest:Lymphoma, hematologic malignancies and stem cell transplantation

2. Current projects underway:a. Completing work on lymphoma bookletb. Analyzing and writing manuscript for Phase II lymphoma trial for SWOGc. Collaborating with colleagues at MD Anderson Cancer Center to complete manuscripts regarding

original observations in patients with lymphoma

3. Grant support available: (Title of grant, all investigators, source of support, dates and amount.)a.) Previous grants:

American Cancer Society, 1990-91, $10,000

Competitive Research Award, University of Texas M.D. Anderson Cancer Center, 1991-92, $3,300.Sandoz Research Fellow Award, 1991-92, $30,000.Competitive Research Award, University of Texas M.D. Anderson Cancer Center, 1991-92, $3,500.Competitive Research Award, UTMDACC, 1991-92, $3,300.

4. Grant support available:a) Previous grants (continued):

American Cancer Society Research Fellowship, 1992-93, $3,600.b.) Current grants:c.) Pending grant proposals: (i.e. those written and submitted)

Teaching Activities:Fall 1994 Oncologic Emergencies, Junior TutorialSpring 1995 Oncologic Emergencies, Junior Tutorial - 3 sessionsFall 1995 Oncologic Emergencies, Junior Tutorial - 3 sessionsSpring 1996 Oncologic Emergencies, Junior Tutorial - 3 sessionsFall 1996 Oncologic Emergencies, Junior Tutorial - 3 sessionsSpring 1997 Oncologic Emergencies, Junior Tutorial - 3 sessionsFall 1997 Oncologic Emergencies, Junior Tutorial - 3 sessionsSpring 1998 Oncologic Emergencies, Junior Tutorial - 3 sessionsSpring 1995 4 months Resident Oncology AttendingFall 1995 2 months Resident Oncology AttendingSpring 1996 5 months Resident Oncology AttendingFall 1996 4 months Resident Oncology AttendingSpring 1997 3 months Resident Oncology AttendingFall 1997 3 months Resident Oncology AttendingSpring 1998 5 months Resident Oncology AttendingFall 1998 4 months Resident Oncology AttendingSpring 1997 7 lectures for Residents' Core Curriculum Series

2/07p&tforma.frm


Administration: (List department committees, KUMC, VAMC, and University committees on which you serve or have served in the past. Describe any other administrative responsibility you carry.)

Dates OrganizationUniversity of Kansas School of Medicine

1985 Multidisciplinary Cancer Committee Representative1984-85 Medical Students' Assembly1984-85 Blood Drive-Hepatavax Information Committee1984-86 Jayhawker MD Yearbook Committee

University of Kansas School of Medicine-Wichita1986-87 Community Relations Committee Representative1986-87 Research Committee

University of Texas, M.D. Anderson Cancer Center1992-93 Chief Fellow1993-94 Lymphoma Section Clinic Liaison to Office of Managed Care1993-94 Clinic Chief, Section of Lymphoma1993-94 Committee on Managed Care1993-94 Ad Hoc Committee on Marketing1994 Alternate, Physician Advisor for Section of Bone Marrow Transplantation

Manuscripts already published:

a. Moore D: The importance of the monocyte in patients with breast cancer. 1984 Medical Student Research Training Program, KUMC 1984 Fall;5:296-323.

b. Pazdur R, Bready B, Moore DF Jr: Clinical trials of fluorouracil with alpha-interferon in advanced colorectal carcinomas. Semin Oncol 1991 Oct.;18(5 Suppl 7):67-70.

c. Pazdur R, Moore DF Jr, Bready B: The modulation of fluorouracil with recombinant alpha interferon: the M.D. Anderson clinical trial. Semin Oncol 1991;18(Suppl 7):67-70.

d. Pazdur R, Moore D, Bready B: Modulation of fluorouracil with recombinant alpha interferon: M.D. Anderson clinical trial. Semin Oncol 1992;19(2 Suppl 3):176-179.

e. Moore DF Jr, Pazdur R, Daugherty K, Tarassoff P, Abbruzzesse JL: Phase II study of gemcitabine in advanced colorectal carcinoma. Invest New Drugs 1992 Nov;10(4):323-325.

f. Moore DF Jr, Pazdur R: Phase I study of 5-fluorouracil with folinic acid combined with recombinant human granulocyte-macrophage colony stimulating factor. Am J Clin Oncol 1992 Dec;15(6):464-466.

g. Pazdur R, Newman RA, Newman BM, Fuentes A, Benvenuto J, Bready B, Moore D, Jaiyesimi I, Vreeland F, Raber MN: Phase I trial of taxotere (RP 56976, NSC 628503): Five-day schedule. J Natl Cancer Inst 1992;84:1781-1788.

h. Moore D, Pazdur R: Systemic therapies for unresectable primary hepatic tumors. J Surg Oncol 1993;3(Suppl):112-114.

i. Moore DL Jr, Sears DA: Pica, iron deficiency, and the medical history. Am J Med 1994;97:390-393.

j. Moore DF, Pazdur R, Abbruzzese JL, Ajani JA, Dubovsky DW, Wade JL 3rd, Belt RJ, Mangold C, Bready B, Winn RJ: Phase II trial of edatrexate in patients with advanced pancreatic adenocarcinoma. Ann Oncol 1994 Mar;5(3):286-287.

k. Pazdur R, Moore DF, Bready B, Giannone L, Maldonado A, Lin YG, Fueger RH, Winn RJ, Levin B: Phase II trial of edatrexate in patients with advanced hepatocellular carcinoma. Ann Oncol 1994 Sept;5(7):646-648.

2/07p&tforma.frm


l. Moore DF Jr, Pazdur R, Abbruzzese JL: A Phase II trial of intravenous melphalan in advanced colorectal carcinoma. Invest New Drugs 1994;12:133-136.

m. Moore DF, Kalvakolanu DV, Lippman SM, Kavanagh JJ, Hong WK, Borden EC, Paredes-Espinoza M, Krakoff IH: Retinoic acid and interferon in human cancer: Mechanistic and clinical studies. Semin Hematol 1994;31(Suppl 5):31-37.

n. Romaguera JE, Rodriguez MA, Hagemeister FB, McLaughlin P, Swan F, Moore DF Jr, Sarris AH, Younes A, Hill D, Cabanillas F: A phase II trial of oral etoposide with mitoxantrone and ifosfamide/mesna consolidated with intravenous etoposide, methylprednisolone, high-dose arabinoside, and cisplating as salvage therapy for relapsing and/or refractory lymphomas. Inv New Drugs 1994;12(3):217-222.

o. Romaguera JE, Sarris AH, Swan F Jr, Younes A, Hagemeister FB, McLaughlin P, Rodriguez MA, Moore DF Jr, Cabanillas F: Phase II study of protracted 5-fluorouracil infusion in patients with relapsing or refractory lymphoma. J Infus Chemother 1994;4:173-176.

p. Duvic M, Moore D, Menter A, Vonderheid EC: Cutaneous T cell lymphoma in association with silicone breast implants and polyurethane: A report of four cases. J Am Acad Dermatol 1995 Jun;32(6):939-942.

q. Moore DF Jr, Moulopoulos LA, Dimopoulos MA: Waldenstrom macroglobulinemia presenting as a renal or perirenal mass: Clinical and radiographic features. Leuk Lymphoma 1995 Apr;17(3-4):331-334.

r. Younes A, Sarris A, Melnyk A, Romaguera J, McLaughlin P, Swan F, Rodriguez A, Hagemeister F, Moore D, North L, Smith TL, Cabanillas F: Three hour paclitaxel infusion in patients with refractory and relapsed non-Hodgkin's lymphoma. J Clin Oncol 1995;13(3):583-587.

s. Moore DF Jr, Vadhan-Raj S: Sustained response in Felty's syndrome to prolonged administration of recombinant human granulocyte macrophage colony-stimulating factor (rhGM-CSF). Am J Med 1995;98(6):591-594.

t. Moore DF Jr, Pazdur R, Sugarman S, Jones D 3rd, Lippman SM, Bready B, Abbruzzese JL: Pilot phase II trial of 13-cis-retinoic acid and interferon- combination therapy in advanced pancreatic adenocarcinoma. Am J Clin Oncol (CCT) 1995 Dec;18:(6):525-527.

u. Sarris AH, Younes A, McLaughlin P, Moore D, Hagemeister F, Swan F, Rodriguez MA, Romaguera J, North L, Mansfield P, Callendar D, Mesina O, Cabanillas F: Cyclosporin A does not reverse clinical resistance to paclitaxel in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol 1996;14(1):233-239.

v. Beran M, Kantarjian H, O'Brien S, Koller C, Al-Bitar M, Arbuck S, Pierce S, Moore D, Abburzzese JL, Andreeeff M, Keating M, Estey E: Topotecan, a topoisomerase-1 inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 1996;88:2473-2479.

w. w. Van Besien KW, de Lima M, Giralt SA, Moore DF Jr, Khouri IF, Rondon G, Mehra R, Andersson BS, Dyer C, Clearly K, Przepiorka D, Gajewski JL, Champlin RE: Management of lymphoma recurrence after allogeneic transplantation: The relevance of graft versus lymphoma effect. Bone Marrow Transplant 1997 May;19(10):977-982.

x. Reddy SP, Harwood RM, Moore DF, Grimm EA, Murray JL, Vadhan-Raj S: Recombinant interleukin-2 in combination with recombinant interferon- in patients with advanced malignancy: A phase 1 study. J Immunother 1997;20(1):79-87.

y. Moore DF Jr, Cabanillas F: Staging and prognostic factors in non-Hodgkin’s lymphoma. Oncology 1998 Oct;12(10 Suppl 7):1-8.

z. Weiss GR, Liu PY, Alberts DS, Peng YM, Fisher E, Xu MJ, Scudder SA, Baker LH, Moore DF, Jr., Lippman SM: 13-cis-retinoic acid or all-trans-retinoic acid plus interferon- in recurrent cervical cancer: A Southwest Oncology Group Phase II randomized trial. Gynecol Oncol 1998:71:386-390.

2/07p&tforma.frm


aa. Pazdur R, Medgyesy DC, Dakhil SR, Moore DF Jr, Scalzo A, Hoff PM, Arbuck SG, Abbruzzese JL: Phase II trial of 9-aminocamptothecin (NSC 603071) administered as a 120-hour continuous infusion weekly for three weeks in metastatic colorectal carcinoma. Invest New Drugs 1999;16(4):341-346.

bb. Samlowski WE, LeBlanc M, Kuebler PJ, Mandanas RA, Mangan KF, Moore DF Jr, Schuller DE, Ensley JF: Evaluation of Tomudex in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: A Southwest Oncology Group Study. Invest New Drugs 1999;16(3):271-274.

cc. Moore DF Jr., Brown TD, LeBlanc M, Dahlberg S, Miller TP, McClure S, Fisher RI: Phase II trial of Menogaril in non-Hodgkin’s lymphomas: A Southwest Oncology Group trial. Invest New Drugs 1999;17(2):169-172.

dd. Poplin EA, Liu PY, Delmore JE, Wilczynski S, Moore DF Jr, Potkul RK, Fine BA, Hannigan EV, Alberts DS: Phase II trial of oral Etoposide in recurrent or refractory endometrial adenocarcinoma: A Southwest Oncology Group Study. Gynecol Oncol 1999;74:432-435.

ee. Hesketh PJ, Crowley JJ, Burris HA III, Williamson SK, Balcerzak SP, Peereboom D, Goodwin JW, Gross HM, Moore DF Jr, Livington RB, Gandara DR: Evaluation of docetaxel in previously untreated extensive-stage small cell lung cancer: A Southwest Oncology Group phase II trial. The Cancer Journal from Scientific American 1999;5(4):237-241.

ff. Macdonald JS, Jacobson JL, Modiano M, Moore DF Jr, Gandara DR, Schoder LE, Chapman RA: A phase II trial of Etoposide, Leucovorin, 5-FU, and Interferon alpha 2b (ELFI) + G-CSF for patients with pancreatic adenocarcinoma: A Southwest Oncology Group Study (SWOG-9413). Investigational New Drugs 2000; 18:269-273.

gg. Chauncey TR, Rankin C, Anderson JE, Chen I, Kopecky KJ, Godwin JE, Kalaycio ME, Moore DF Jr, Shurafa MS, Petersdorf SH, Kraut EH, Leith CP, Head DR, Luthardt FW, Willman CL, Appelbaum FR: A phase I study of induction chemotherapy for older patients with newly diagnosed acute myeloid leukemia (AML) using mitoxantrone, etoposide, and MDR modulator PSC833: A Southwest Oncology Group study 9617. Leukemia Research 2000; 24:567-574.

hh. HhWeick JK, Crowley JJ, Hussein MA, Moore, DF, Barlogie B: The evaluation of gemcitabine in resistant or relapsing multiple myeloma, phase II: A Southwest Oncology Group study. Invest New Drugs 2002;20:117-121.

ii. Alberts SR, Townley PM, Goldberg RM, Cha SS, Moore, DFJ, Krook JE, Buckner JC, Fitch TR, Wiesenfeld M, Mailliard JA: Gemcitabine and Oxaliplatin for Metastatic Pancreatic Cancer: A North Central Cancer Treatment Group (NCCTG) Phase II Study. Annals of Oncology 2003;14: 580-585.

jj. Roscoe JA, Morrow GR, Hickok JT, Bushunow PW, Pierce HI, Flynn PJ, Kirshner JJ, Moore DF Jr, Atkins JN: The efficacy of acupressure and acustimulation wrist bands for the relief of chemotherapy-induced nausea and vomiting: A URCC CCOP multicenter study. Journal of Pain & Symptom Management 2003; 26(2):731-742.

kk. Hofman M, Morrow GR, Roscoe JA, Hickok JT, Mustian KM, Moore DF, Wade JL, Fitch TR: Cancer patients’ expectations of experiencing treatment-related side effects. A University of Rochester Cancer Center Community Clinical Oncology Program Study of 938 patients from community practices. Cancer 2004; 101(4):851-857.

ll. Alberts SR, Schroeder M, Erlichman C, Steen PD, Foster NR, Moore DF, Rowland KM, Nair S, Tschetter LK, Fitch TR: Gemcitabine and ISIS-2503 for patients with locally advanced or metastatic pancreatic adenocarcinoma: A North Central Cancer Treatment Group Phase II trial. Journal of Clinical Oncology 2004; 22(24):4944-4950.

2/07p&tforma.frm

sbuller, 01/03/-1,

Need to see if this is a peer reviewed journal for future promotion and tenure purposes.


mm. Loprinzi CL, Levitt R, Barton DL, Sloan JA, Atherton PJ, Smith DJ, Dakhil SR, Moore Jr DF, Krook JE, Rowland KM, Mazurczak MA, Berg AR, Kim GP: Evaluation of shark cartilage in patients with advanced cancer: a North Cancer Clinical Trial Group trial. Cancer 2005;104(2):176-182.

nn. Barlogie B, Kyle RA, Anderson KC, Greipp PR, Lazarus HM, Hurd DD, McCoy J, Moore DF, Lanier KS, Chapman RA, Cromer JN, Salmon SE, Durie B, Crowley JC: Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: Final results of phase III US intergroup trial S9321. Journal of Clinical Oncology 2005; 929-936.

oo. Loprinzi CL, Levitt R, Barton DL, Sloan JA, Atherton PJ, Smith DJ, Dakhil SR, Moore Jr DF, Krook JE, Rowland KM, Mazurczak MA, Berg AR, Kim GP: Evaluation of shark cartilage in patients with advanced cancer: a North Cancer Clinical Trial Group trial. Cancer 2005;104(2):176-182.

Manuscripts in Press:

Kelly K, Crowley J, Presant C, Grevstad P, Bunn P, Wozniak A, Weiss G, Moore D, Raghaven D, Livingston R, Gandara D: A randomized Phase III trial of Paclitaxel plus carboplatin versus vinorebine plus cisplatin in the treatment of patients with advanced non-small cell lung cancer: A Southwest Oncology Group trial

Manuscripts submitted but not yet accepted:

a. Pazdur R, Bready B, Moore D, Ajani JA, Abbruzzesse J, Sugarman S, Markowitz A, Jones D, Levin B: Phase II trial of isotretinoin and recombinant interferon in metastatic colorectal adenocarcinoma. (submitted)

b. Garces YI, Okuno SH, Schild SE, Mandrekar SJ, Bot BM, Martens JM, Wender DB, Soori GS, Moore DF, Kozelsky TF, Jett JR: Phase I NCCTG trial-N9923 of escalating doses of twice daily thoracic radiation therapy with amifostine and with alternating chemotherapy in limited stage small cell lung cancer (submitted to International Journal of Radiation Oncology, Biology and Physics, May 2006)

c. Jatoi A, Martenson JA, Foster N, McLeod HL, Lair BS, Brindle JS, Nichols F, Tschetter LK, Moore DF, Fitch TR, Alberts SR : Paclitaxel, carboplatin, 5-fluorouracil and radiation for locally advanced esophageal cancer : Phase II results of pharmacologic and molecular efforts to mitigate toxicity and predict outcomes (NCCTG N0044, submitted June 2006)

d. Jatoi A, Moore DF, Nguyen PL, Sloan JA, Kugler JW, Rowland KM, Soori GS, Wender DB, Fitch TR, Novotny PJ, Loprinzi CL: A placebo-controlled double-blind trial of etanercept for cancer anorexia/weight loss syndrome: Results from N00C1 form the North Central Cancer Treatment Group (submitted July 2006)

e. Johnson EA, Marks RS, Maddrekar SJ, Hillman SL, Hauge MD, Bauman MD, Wos EJ, Moore DF, Kugler JW, Windschitl HE, Rowland KM, Bernath AM, Fitch TR, Soori GS, Jett JR, Adjei AA, Perez EA: Phase III randomized, double-blind study of maintenance CAI or placebo in patients with advanced non-small cell lung cancer after completion of initial therapy (NCCTG 97-24-51) (submitted JCO July 2006)

f. Haddock MG, Swaminathan R, Foster N, Alberts SR, Hauge MD, Martenson JA, Fitch TR, Stella PJ, Tenglin RC, Schaefer PL, Moore DF: Gemcitabine, cisplatin and radiation therapy for patients with locally advanced pancreatic adenocarcinoma: A North Central Cancer Treatment Group phase II study, N9942. (submitted 9/06)

g. Jatoi A, Martenson JA, Foster N, McLeod HL, Lair BS, Nichols F, Tschetter LK, Moore DF, Fitch TR, Alberts SR: Paclitaxel, carboplatin, 5-fluorouracil and radiation therapy for locally advanced esophageal cancer: Phase II results of pharmacologic and molecular efforts to mitigate toxicity and predict outcomes (North Central Cancer Treatment Group Study, N0044). (submitted to American Journal of Clinical Oncology 12/06)

h. Keller S, Moore DF, others??: Prospective randomized phase III trial of postoperative adjuvant therapy in patients with completely resected stage II-IIIA non-small cell lung cancer. (ECOG E3501) (submitted 10/06)

2/07p&tforma.frm


Other Publications:

a. Moore D, Cabanillas F: What constitutes a “cure” in lymphoma? [Editorial] Leuk Lymphoma 1993 Oct;11(304):161-163

b. Moore DR Jr, Buescher S, Vadhan-Raj S: Interleukin-1 alpha administration increases oral granulocytes and epithelial cells. [Letter] J Infect Dis 1994;169(6):1419-1420.

c. Moore DF Jr, Huber M, Lippman SM, Hagemeister FB: Merkel cell carcinoma as a second primary tumor in a patient with non-Hodgkin’s lymphoma. Cancer Bulletin 1995;47:175-177.

d. Moore DF Jr, Swan F, Yau J, Rodriguez MA, McLaughlin P, Sarris A, Romaguera J, Younes A, Hagemeister FB, Cabanillas F: Cyclosporine plus doxorubicin, vincristine and etoposide in the treatment of refractory non-Hodgkin’s lymphoma: A phase II study. Clin Oncol R Coll Radiol 1995;7(5):300-303.

e. Robbins WA, Meistrich ML, Moore D, Hagemeister FB, Weier HU, Cassel MJ, Wilson G, Eskenazi B, Wyrobek AJ: Chemotherapy induces transient sex chromosomal and autosomal aneuploidy in human sperm. Nat Genet 1997 May;16:74-78. [Letter]

Books and Book Chapters:

1. Moore DF Jr, Andreeff M: The acute leukemias, in Pazdur R (ed): Medical Oncology: A Comprehensive Board Review. Philadelphia (Huntington, NY), PRR Inc, 1993, pp 3-28.

2. Moore DF Jr, Mitsuyasu R: HIV-associated malignancies, in Pazdur R (ed): Medical Oncology: A Comprehensive Board Review. Philadelphia (Huntington, NY), PRR Inc, 1993, pp 379-393.

3. Moore DF Jr, Lee JS: Staging classification and prognostic factors for non-small cell lung carcinoma, in Pass HI, Mitchell J, Johnson DH, Turrisi AT (eds): Lung Cancer: Principles and Practice. Philadelphia, JB Lippincott, 1995, pp 481-495.

4. Moore DF Jr, Vadhan-Raj S: Hematopoietic growth factors in bone marrow failure states, in Treatment of Radiation Injuries. New York, Plenum Press (in press).

5. Moore DF Jr, Lippman SM, Kalvakolanu DVR, Borden EC, Kavanagh JJ, Paredes-Espinoza M, Schleuniger U, Massimini G, Holdener E, Hong WK, Krakoff IH: Retinoic acid and interferon combination strategies in solid tumors: Rationale and results, in Differentiation Therapy. Rome, Serono Symposia Publications (in press).

6. Moore DF Jr (ed): Clinicians’ Guide to Lymphoma; PRR, Inc 1997 (in press).

Published Abstracts:

1. Moore D, Pazdur R, Daugherty K, Gutterman J, Levin B: A phase I study of 5-fluorouracil with folinic acid combined with recombinant human granulocyte-macrophage colony stimulating factor. Proc Am Soc Clin Oncol 1991;10:1121 (#318).

2. Moore D, Estey E: Prognostic value of the day 14 bone marrow examination in newly diagnosed acute myelogenous leukemia. Blood 1991;78(Suppl 1):457a (#1820).

3. Pazdur R, Gomez J, Schmidt S, Bready B, Moore D Jr, Light S, Mott D, Zhi J, Satoh H, Min B: Phase I pharmacokinetic study of fluorouracil (FU) and recombinant alpha-2A interferon (IFN). Proc Am Soc Clin Oncol 1993;12:152a (#408).

4. Jaiyesimi I, Pazdur R, Ho DH, Lassere Y, Moore D Jr, Bready B, Krakoff IH: Phase I trials of UFT (Ftorafur plus Uracil) and Leucovorin: 28 day schedule. Proc Am Soc Clin Oncol 1993;12:152a (#409).

2/07p&tforma.frm


5. Bready B, Pazdur R, Sugarman S, Abbruzzesse J, Jones D, Moore D Jr: Phase II study of recombinant alpha-2a interferon and isotretinoin in patients with advanced colorectal carcinoma. Proc Am Soc Clin Oncol 1993;12:214a (#652).

6. Moore D Jr, Pazdur R, Bready B, Giannone L, Lin YG, Maldonado A, Winn R: Phase II trial of edatrexate in advanced hepatocellular carcinoma. Proc Am Soc Clin Oncol 1993;12:216a (#653).

7. Moore D Jr, Pazdur R, et al: UFT and high dose leucovorin every 28 days: A phase I study. Proc Am Assoc Cancer Res 1993;34.

8. Moore D Jr, Swan F, Yau J, Rodriguez MA, McLaughlin P, Hagemeister F, Romaguera J, Katz RL, Huh YO, Sniege N, Redman JR, Velasquez WS, Grenko RT, Ordonez N, Cabanillas F: Cyclosporine plus doxorubicin, vincristine, and VP-16 in the treatment of refractory non-Hodgkin's lymphoma: A phase II study. Proc Am Soc Clin Oncol 1994;13:389 (abst #1325).

9. Younes A, Sarris A, McLaughlin P, Romaguera J, Jendiroba D, Swan F, Rodriguez A, Hagemeister F, Moore D, Cabanillas F: Phase II trial of taxol given as 3-hour infusion schedule every 3 weeks in relapsed non-Hodgkin's lymphoma (NHL). Proc Am Soc Clin Oncol 1994;13:374(abstr #1267).

10. Carrum G, Moore D, Hagemeister FB, Crow MK, Cabanillas F: Clinical features and outcome for patients (pts) 60 years and older with Hodgkin's disease (HD). Proc Am Soc Clin Oncol 1994;13:389(abstr #1324).

11. McLaughlin P, Hagemeister FB, Sarris A, Romaguera J, Pate O, Younes A, Swan F, Moore D, Cabanillas F: Fludarabine, mitoxantrone, and dexamthasone (FND) for recurrent low-grade lymphoma (LGL): A phase II trial. Proc Am Soc Clin Oncol 1994;13:387(abstr #1318).

12. Moore D Jr, Pazdur RP, Sugarman S, Jones D III, Lippman SM, Bready B, Abbruzzesse JL: Pilot phase II trial of 13-cis-retinoic acid and interferon-alpha in advanced pancreatic adenocarcinoma. Proc Am Soc Clin Oncol 1995.

13. Moore DF Jr, Hagemeister FB: Clinical characteristics and outcome of Hodgkin's disease in 125 patients 60 years of age and older. Blood 1994;84(Suppl 1):163a(#637).

14. Sarris AH, Younes A, McLaughlin P, Moore D, Hagemeister F, Swan F, Rodriguez MA, Romaguera J, North L, Cabanillas F: Cyclosporin A does not reverse clinical resistance to Paclitaxel (Taxol) in patients with relapsed non-Hodgkin's lymphoma. Blood 1994;84(Suppl 1):167a(#654).

15. Romaguera JE, Sarris AH, Swan F Jr, Younes A, McLaughlin P, Rodriguez MA, Moore DF, Cabanillas F: Phase II study of 5-fluorouracil by protracted infusion in patients with relapsing or refractory lymphoma. Blood 1994;84(Suppl1):647a(#2573).

16. Moore DF Jr, Moore DF Sr, Johnson DB, Cannon MW, Whisman SA, Church PS, Palko W, Dakhil S, Hynes HE: Bethesda Unit Titer as a prognostic factor for patients with acquired factor VIII inhibitors. Blood 1994;84(Suppl 1):680a(#2705).

17. Moore DF Jr, Moore DF Sr, Diener C, Armstrong L, Slavik M, Watson E, Martin L, Peterson M: Efficacy of granisetron (Kytril) for chemotherapy-associated nausea and vomiting in a VA teaching hospital. Proc Am Soc Clin Oncol 1995;14:534(#1762).

18. Hewitt St, Moore DF Jr: Black (hairy) tongue as an indicator of poor outcome in patients with advanced malignancy. Proc Am Soc Clin Oncol 1995;14:498(#1631).

19. Abdallah JG, Moore DF Jr, Minns GO: Enteric-associated T-cell lymphoma (EATCL) as an unusual presentation of Helicobacter pylori associate "MALT" lymphoma. Presented at the American College of Physicians Kansas Regional Meeting, September 8-9, 1995 in Wichita, Kansas by Dr. Abdallah.

2/07p&tforma.frm


20. Moore DF Jr, Moore DF Sr, Johnson DB, Bluml P, Cannon MW, Dakhil SR, Palko W, Hynes HE: Interleukin-2 (IL-2) therapy following autologous blood and marrow transplantation in Burkitt's lymphoma: Effect on lymphocyte subsets. Proc of Second Pan-Pacific Lymphoma Conference 1995.

21. Moore DF Jr, Moore DF Sr, Diener C, Armstrong L, Slavik M, Watson E, Martin L, Peterson M: Efficacy of granisetron (Kytril) for chemotherapy-associated nausea and vomiting in a VA teaching hospital. Proc Am Soc Clin Oncol 1995;14:534(#1762).

22. Wu J, Moore D Jr, Stobaugh J, Slavik M: Pharmacokinetic modeling of Etoposide (VP-16) administered by short intravenous infusion. Fifth Annual Research Forum, University of Kansas School of Medicine-Wichita, Book of Abstracts 1995;5:6.

23. Wu J, Svojanovsky S, Moore D Jr, Stobaugh J, Slavik M: Pharmacokinetic modeling of Taxol administered by clinically used intravenous infusional schedules. Fifth Annual Research Forum, University of Kansas School of Medicine-Wichita, Book of Abstracts 1995;5:8.

24. Lee BG, Moore DF Jr, Fleming RH: Response to immunomodulation in a patient with cardiac transplant associated non-hodgkin's lymphoma (NHL): Role of lymphocyte sub-populations in serial reduction in immunosuppression Presented to the American College of Physicians Kansas Regional Meeting, September 6-7, 1996, in Overland Park, Kansas by E. Magana.

25. Nelson TL, Schulz TK, Moore DF Jr, Moore DF Sr, Hartman K, Rohlman V: Hemolytic anemia secondary to the bite of a brown recluse spider: Case reports and a review of the literature. Presented to the American College of Physicians Kansas Regional Meeting, September 6-7, 1996, in Overland Park, Kansas by T. Nelson.

26. Ramsey TC, Moore DF Jr: Evaluation of hemolytic anemias. Presented to the American College of Physicians Kansas Regional Meeting, September 6-7, 1996, in Overland Park, Kansas by T. Ramsey.

27. Schmidt DR, Moore D Jr, Moore DF Sr, Kovach KL, Weber HP Jr: Severe metabolic acidosis associated with the therapeutic use of Interleukin-2 in non-Hodgkin's lymphoma. Presented to the American College of Physicians Kansas Regional Meeting, September 6-7, 1996, in Overland Park, Kansas by D. Schmidt.

28. Tran SM, Moore DF Jr, Cabanillas F: Prognostic implications following an indeterminate nondiagnostic workup of lymphoma. Presented to the American College of Physicians Kansas Regional Meeting, September 6-7, 1996, in Overland Park, Kansas by S. Tran.

29. Moore DF Jr, Schmidt DR, Moore DF Sr, Kovach KL, Weber HP Jr: Severe metabolic acidosis associated with the therapeutic use of interleukin-2 in non-Hodgkin's lymphoma. Blood 1996;88(Suppl 1):#3868.

30. Moore DF Jr, Preti A, Tran SM, Hagemeister FB, Rodriguez MA, McLaughlin P, Romaguera J, Sarris A, Younes A, Moore DF Sr, Cabanillas F: Prognostic implications following an indeterminate nondiagnostic workup of lymphoma. Blood 1996;88(Suppl 1):#906.

31. Lee BG, Moore DF Jr, Fleming RH: Response to immunomodulation in patients with cardiac transplant associated non-Hodgkin's lymphoma (NHL): Role of lymphocyte sub-populations in serial reduction in immunosuppression. Presented to the American College of Physicians Kansas Regional Meeting, September 5-6, 1997, in Wichita, Kansas by E. Magana.

32. McKee JW, Moore DF Jr: Glioblastoma multiforme: Is there increased incidence in Southwest Kansas? Presented to the American College of Physicians Kansas Regional Meeting, September 5-6, 1997, in Wichita, Kansas by J. McKee who won a second place award in the residents competition.

2/07p&tforma.frm


33. Medgyesy D, Dakhil S, Moore D, Scalzo A, Hoff PM, Abburzzese J, Winn R, Pazdur R: A phase II trial of a 5-day continuous infusion of 9-aminocamptothecin (9-AC) weekly for 3 weeks in patients with advanced colorectal carcinoma. Proceedings of the Tenth Annual NIC-EORTC Symposium on New Drugs in Cancer Therapy, June 16-19, 1998, Amsterdam.

34. Chauncey TR, Rankin C, Anderson JE, Godwin JA, Kalaycio M, Moore DF, Petersdorf SH, Shurafa MS, Kraut EH, Head DR, Slovak ML, Willman CL, Appelbaum FR: A phase I dose-finding study of induction chemotherapy for older patients with newly diagnosed acute myeloid leukemia (AML) using mitoxantrone (M), etoposide (E), and the MDR modulator PSC833: Southwest Oncology Group Study #9617. Proceedings of American Society of Hematology Fortieth Annual Meeting, December 4-8, 1998, Miami Beach, Florida.

35. Chauncey TR, Rankin C, Anderson JE, Godwin JA, Kalaycio M, Moore DF, Petersdorf SH, Shurafa MS, Kraut EH, Head DR, Slovak ML, Willman CL, Appelbaum FR: A phase I dose-finding study of induction chemotherapy for older patients with newly diagnosed acute myeloid leukemia (AML) using mitoxantrone (M), etoposide (E), and the MDR modulator PSC833: Southwest Oncology Group Study #9617. Blood 1998; 92(10)(Suppl. 1): 231a(#945).

36. Morrow GR, JT Hickok, Lindke JL, Moore DF Jr., Wichita CCOP, Rousey S, Metro-Minnesota CCOP, Banerjee TK, Marshfield Medical Research Foundation CCOP, Wade P, Greater Phoenix CCIOP, University of Rochester Cancer Center, CCOP Research Base, Rochester NY: Longitudinal Assessment of Fatigue in Consecutive Chemotherapy Patients: A URCC CCOP Study. Proceedings of ASCO 1999;18:593a(2293).

37. Aguayo A, Kraut EH, Moore DF, Wright JJ, Jones D, Winn R, Pazdur R: Phase II study of Dolastatin 10 administered intrvenously every 21 days to patients with metastatic colorectal cancer. American Society of Clinical Oncology (ASCO) Proceedings 2000;19:288a (abstract #1127).

38. Saad ED, Kraut EH, Paula HM, Moore Jr DF, Jones D, Pazdur R, Abbruzzese JL: Phase II Study of Dolastatin-10 as First-Line Treatment for Advanced Colorectal Cancer. American Journal Clinical Oncology (CCT), Vol. 25, No. 5, 2002.

39. Alberts SR, Townley PM, Cha S, Moore DF Jr, Krook JE, Fitch TR, Sargent DJ, Goldberg RM: Oxaliplatin and gemcitabine for patients with pancreatic adenocarcinoma: a NCCTG phase II study. Proc of Am Soc Clin Oncol 2002;21:152a.

40. Ghabach BS, Moore DF Jr,: Glanzmann’s Patient with Acute Intra-Abdominal Bleeding; Successful Use of Recombinant Factor VII: Blood 2003;102:79b Abstract #4024.

41. Ghabach BS, Moore DF, Jr,: Langerhans Cell Histiocytosis: A Variety of Clinical Presentations and Treatment Options: Blood 2003;102:287b Abstract #4869.

42. Ghabach BS, Moore DF, Jr,: Waldenstrom Macroglobulinemia Presenting as a Gastric Mass: Blood 2003;102:366b Abstract #5191.

43. Roscoe JA, Morrow GR, Hickok JT, Bushunow P, Pierce HI, Flynn PJ, Kirshner JJ, Moore DF Jr., Atkins JN: The Efficacy of Acupressure and Acustimulation Wrist Bands for Chemotherapy-Induced Nausea and Vomiting: A University of Rochester Cancer Center CCOP. Journal of Pain and Symptom Management. August 2003;26 #731.

44. Goyle KK, Moore DF Jr., Garrett C, Goyle V: Benign Metastasizing Leiomyomatosis: American Journal of Clinical Oncology 2003;Vol 25, #5, October.

45. Hofman M, Roscoe JA, Hickok JT, Morrow GR, Moore DF, Wade JL, Fitch T: Impact of information sources on expectation of cancer treatment side effects. A URCC CCOP Study. ASCO 12/15/03; Control/Tracking Number 04-AB-682-ASCO.

2/07p&tforma.frm


46. Flinn IW, Kumm E, Grever MR, Neuberg D, Dewald GW, Bennett JM, Paietta EM, Appelbaum FR, Larson RA, Hussein MA, Moore DF, Tallman MS: Fludarabine and cyclophosphamide produces a higher complete response rate and more durable remissions than fludarabine in patients with previously untreated CLL: Intergroup trial E2997. Blood (suppl 1) 104:139a (abstract # 475), 2004.

47. Garces YI, Okuno SH, Schild SE, Mandrekar SJ, Mailliard JA, Kahanic SP, Rao RM, Moore DF, Kozelsky TF, Jett JR: A phase I/II NCCTG trial of escalating doses of twice daily thoracic radiation therapy (TRT) in limited-stage small cell lung cancer (LSCLC). Proc Am Soc Clin Oncol 23:16 (abstract #7163), 661s, 2005.

Poster Exhibits:

1. Moore D Jr, Pazdur R, Bready B, Dubovsky D, Wade J III, Belt R, Winn R: Phase II trial of Edatrexate (10-EdAM) in advanced pancreatic carcinoma. Proc Am Assoc Cancer Res 1993;34 (Abstr. #1202). [Poster presentation]

2. Moore D Jr, Andreeff M, Mahadevia R, Van N, Zhao S, Goodacre A, Jeha S, Vadhan-Raj S: Effects of the fusion protein PIXY321 on the proliferation of bone marrow cells in patients with Diamond-Blackfan anemia. Blood 1993;82(Suppl 1):(Abstr. 341). [Poster presentation].

3. Moore DF Jr, Van N, Andreeff M, Jeha S, Mahadevia R, Van N, Zhao S, Vadhan-Raj S: Effects of the fusion protein (PIXY321 on proliferation of bone marrow (BM) cells in BM failure states. Proc Am Soc Clin Oncol 1994;13:298 (abst #972). [Poster presentation].

4. Dakhil SR, Hynes HE, Cannon MW, Johnson DB, Moore DF Jr: G-CSF plus ciprofloxacin in the prevention of sepsis in patients with severe neutropenia related to chemotherapy. Blood 1994;84(Suppl1):24a(#83). [Poster presentation].

5. Witzig TE, Geyer SM, Salim M, Inwards DJ, Fonseca R, Kaufmann SH, Kurtin P, Colgan JP, Call TG, Moore, DF Jr, White WL: A Phase II Trial of the Rapamycin Analog CCI-799 in Previousley Treated Mantle Cell Non-Hodgkin’s Lymphoma: Interim Analysis of 18 Patients. Journal of the American Society of Hematology 2003;102 643a (abstract #2374). Poster Presentation #Session: 545-II.

Scientific papers presented at national and international meetings:

a. Phase II study of edatrexate in pancreatic adenocarcinoma, 5/20/93, American Association for Cancer Research, Orlando, FL, (as poster).

b. Effects of the fusion protein PIXY321 on the proliferation of bone marrow cells in patients with Diamond-Blackfan anemia, 12/5/93, American Society of Hematology, St. Louis, MO, (as poster).

c. Oncology and Managed Care, 4/20/94, Managed Care Symposium and Case Managers Meeting, Westin-Galleria Hotel, Houston, Texas.

d. Effects of the fusion protein PIXY321 on the proliferation of bone marrow cells in bone marrow failure states, 5/16/94, American Society of Clinical Oncology, Dallas, TX, (as poster).

e. Clinical Characteristics and Outcome of Hodgkin's Disease in 125 patients 60 years of Age and Older, December 1-3, 1994, the American Society of Hematology meeting in Nashville, Tennessee (poster).

f. G-CSF plus ciprofloxacin in the prevention of sepsis in patients with severe neutropenia related to chemotherapy, December 3, 1994, American Society of Hematology, Nashville, Tennessee (poster).

g. Interleukin-2 (IL-2) therapy following autologous blood and marrow transplantation in Burkitt's lymphoma: effect of lymphocyte subsets, July 25-28, 1995, Second Pan-Pacific Lymphoma Conference, Kapalua, Hawaii (poster).

2/07p&tforma.frm


Scientific papers presented at local and regional meetings:

a. Neurocysticercosis, 4/90, Baylor College of Medicine City-Wide Infectious Disease.

b. Castleman's disease, 8/90, Baylor College of Medicine City-Wide Hematology.

c. Soft tissue sarcoma, 4/2/91, University of Texas M.D. Anderson Cancer Center Division of Medicine Grand Rounds.

d. Small round cell tumor, 6/6/91, University of Texas M.D. Anderson Cancer Center Division of Medicine Grand Rounds.

e. Fludarabine therapy and late opportunistic infections, 7/10/91, Baylor College of Medicine City-Wide Hematology.

f. Aplastic anemia, 7/17/91, Baylor College of Medicine City-Wide Hematology.

g. Sézary syndrome, cutaneous lymphomas, and review of HTLV-I as an etiologic agents, 9/91, Baylor College of Medicine City-Wide Hematology.

h. PNH/Ham's Test and Kit Ligand, Fall 1991, Baylor College of Medicine Hematology Case Conferences.

i. Hemolytic disease of the newborn and intrauterine transfusions, 11/13/91, Baylor College of Medicine City-Wide Hematology.

j. Pica in iron deficiency anemia: case report and review of the literature, 1/22/92, Baylor College of Medicine City-Wide Hematology.

k. An update on the acute leukemias, 7/20/92, St. Joseph Medical Center Grand Rounds.

l. AIDS-associated malignancies, 7/23/92, Veterans Administration Medical Center Grand Rounds.

m. Biomarkers in head and neck malignancies, 2/26/93, University of Texas M.D. Anderson Cancer Center Journal Club, Section of Head and Neck and Thoracic Medicine Oncology.

n. Phase II study of edatrexate (10-EdAM) in advanced pancreatic adenocarcinoma, 3/93, University of Texas M.D. Anderson Cancer Center Protocol Meeting.

o. PIXY321 in Diamond-Blackfan anemia, 12/1/93, Baylor College of Medicine City-Wide Hematology.

p. AIDS-associated malignancies, 6/10/94, Temple Veterans Administration Medical Center Grand Rounds (Texas).

q. Update on Lymphomas, 9/6/94, St. Francis Regional Medical Center Internal Medicine Grand Rounds.

r. Update on Lymphomas, 9/16/94, University of Kansas School of Medicine-Wichita Grand Rounds.

s. New Issues in Bone Marrow Transplant, 11/1/94, St. Francis Regional Medical Center Conference.

t. Colon Cancer, 3/27/95, St. Joseph Medical Center Conference.

u. Lymphoma, 4/24/95, St. Joseph Medical Center Conference.

v. Adjuvant Chemotherapy for Breast Cancer, 8/30/95, Via Christi Regional Medical Center-St. Francis Campus Conference.

w. Adjuvant Chemotherapy -- Current Issues, October 6, 1995, Twenty-seventh Annual J.H. Holt Memorial Academic Assembly-Via Christi Regional Medical Center-St. Francis Campus.

x. Panel Discussion: Use of Endoscopy vs Use of Radiology in GI/Colon Malignancies, October 6, 1995, Twenty-seventh Annual J.H. Holt Memorial Academic Assembly-Via Christi Regional Medical Center-St. Francis Campus.

2/07p&tforma.frm


y. Leukemia Update, October 24, 1995, Via Christi Regional Medical Center-St. Francis Campus Grand Rounds.

z. Current Knowledge in Tumor Markers, 10/26/95, Via Christi Regional Medical Center-St. Francis Campus Grand Rounds

aa. Lung Cancer: Evaluation and Prognosis, December 18, 1995, Columbia Wesley Medical Center Grand Rounds.

bb. Anemia, 3/3/97, Columbia Wesley Medical Center Geriatric Series.

cc. Lymphomas, April 22, 1997, Via Christi Regional Medical Center-St. Francis Campus Grand Rounds.

dd. Update on Prostate Cancer Screening and Management, 9/6/97, American College of Physicians Kansas Chapter Meeting, Wichita, Kansas. (State-of-the-Art Lecture)

ee. Stem cell transplantation, 10/5/99, Via Christi Regional Medical Center-St. Francis Campus Grand Rounds.

ff. Lung cancer, 1/24/00, Wesley Medical Center Noon Conference.

Article published without Dr. Moore's name as author:

Pazdur R, Bready B, Moore D, Ajani JA, Abbruzzesse J, Sugarman S, Markowitz A, Jones D, Levin B: Phase II trial of isotretinoin and recombinant interferon in metastatic colorectal adenocarcinoma. Inv New Drugs 1994; ??

2/07p&tforma.frm

View Dr. Moore, Jr.'s Curriculum Vitae in Word Format

Documents

indeterminate

severe neutropenia

mdr modulator

acustimulation

severe metabolic

waldenstrom

weber hp jr

metastatic